Work Here?
About Cardiosense
Industries
AI & Machine Learning
Healthcare
Company Size
11-50
Company Stage
Series A
Total Funding
$15.1M
Headquarters
Chicago, Illinois
Founded
2020
Overview
Cardiosense is focused on improving cardiac care through a non-invasive monitoring platform that uses biometric sensors and artificial intelligence (AI) to analyze heartbeats. This platform captures the electromechanical behavior of each heartbeat, allowing for early detection of declining heart function. By providing healthcare providers with insights into patient conditions before symptoms arise, Cardiosense enables them to prioritize at-risk patients and take proactive measures. Unlike traditional methods that require invasive procedures, Cardiosense's solution is safer and easier to use, making it appealing to hospitals and clinics. The company generates revenue by selling wearable devices and offering subscription access to its analytics platform, ensuring ongoing support for patient monitoring. The goal of Cardiosense is to enhance patient outcomes in cardiac care by preventing severe events through early intervention.
💡 Want to apply to Cardiosense?
You have ways to get a Cardiosense referral from your network.
Get referrals →
Simplify's Take
What believers are saying
- Cardiosense raised $15.1M in Series A funding to accelerate product development.
- The global cardiac monitoring market is projected to grow at a 7.5% CAGR until 2030.
- Recent FDA approvals of AI tools suggest a favorable regulatory environment for Cardiosense.
What critics are saying
- Increased competition from Apple and Fitbit could threaten Cardiosense's market share.
- Regulatory hurdles may delay broader market entry and expansion for Cardiosense.
- Continuous funding is needed for R&D, posing financial risks if future rounds fail.
What makes Cardiosense unique
- Cardiosense offers a non-invasive cardiac monitoring platform using AI and biometric sensors.
- Their platform detects early signs of cardiac decline before symptoms appear.
- Cardiosense's technology provides actionable insights for personalized patient care.
Help us improve and share your feedback! Did you find this helpful?
Funding
Total Funding
$15.1M
Meets
Industry Average
Funded Over
1 Rounds
Industry standards
Benefits
Hybrid Work Options
Relocation Assistance
Growth & Insights and Company News
6 month growth
↑ 0%1 year growth
↑ 0%2 year growth
↑ 18%Cardiosense Receives $15.1M Series A Round Back to HomeCHICAGO, IL, Cardiosense announced that it has raised $15.1 million in Series A funding.Cardiosense, a digital health company leveraging artificial intelligence and multi-sensor devices to enable early detection of cardiovascular disease, announced today that it has raised $15.1 million in Series A funding, co-led by Broadview Ventures and Hatteras Venture Partners, with participation from Laerdal Million Lives Fund, OSF Ventures, UnityPoint Health Ventures, and Portal Innovations. The capital will be used to support team expansion, accelerate product development, and fund an expansive heart failure study.Cardiosense is building a physiological waveform AI platform to develop predictive biomarkers to detect and manage cardiac disease. The Company has developed a suite of novel digital tools, multi-sensor devices, and analysis algorithms to detect early signs of cardiovascular disease, inform personalized therapy, and improve patient outcomes.(c)2011-2020 by Massinvestor, Inc. For contact info, please check out our about page
Cardiosense is Hiring for 3 Jobs on Simplify!
Find jobs on Simplify and start your career today
About Cardiosense
Industries
AI & Machine Learning
Healthcare
Company Size
11-50
Company Stage
Series A
Total Funding
$15.1M
Headquarters
Chicago, Illinois
Founded
2020
Cardiosense is Hiring for 3 Jobs on Simplify!
Find jobs on Simplify and start your career today